FDA Clearance Tracker · P910007
AXSYM TOTAL PSA & ARCHITECT TOTAL PSA
Last checked: Nov 20, 2026Latest source record: Sep 25, 1991 (this decision)Source: openFDAMethods & limitations
Decided
Sep 25, 1991
Approved
Time to decision
208 days
Received Mar 1, 1991. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA
Device class
Class III
The decision
- FDA number
- P910007
- Device name
- AXSYM TOTAL PSA & ARCHITECT TOTAL PSA
- Applicant
- Abbott Laboratories
- Applicant location
- Abbott Park, IL
- Received
- Mar 1, 1991
- Decided
- Sep 25, 1991
- Decision
- Approved
- Supplements
- 67 in FDA's data for this PMA. See them on the FDA record
Device type
- Device type
- Total, prostate specific antigen (noncomplexed & complexed) for detection of prostate cancer (MTF)
- Device class
- Class III
- Specialty
- Laboratory Medicine & Pathology
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code MTF. The earliest in FDA's data is P850048, decided Feb 25, 1986.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
Other decisions for Abbott Laboratories
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- Anti-HCV Next510(k)
K262156 · Decided Sep 23, 2026 · 89 days after receipt
Device type: Assay, Enzyme Linked Immunosorbent, Hepatitis C Virus (MZO) · Laboratory Medicine & Pathology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.